SCHEMBL6600623

SCHEMBL6600623

O=C(NC(Cc1nc2ccccc2c(=O)[nH]1)C(=O)O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.56
PARP3 Q9Y6F1 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
TNKS O95271 1/20 0.54
TNKS2 Q9H2K2 1/20 0.54
KDM4E B2RXH2 2/20 0.52
LMNA P02545 1/20 0.52
PIN1 Q13526 2/20 0.51
KMT2A Q03164 1/20 0.50
IDO1 P14902 1/20 0.49
TDO2 P48775 1/20 0.49
RAB9A P51151 1/20 0.47
PARP2 Q9UGN5 1/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
CTSS P25774 1/20 0.47
CTSK P43235 1/20 0.47
NOS1 P29475 1/20 0.46
ITGB3 P05106 3/20 0.46
ITGA2B P08514 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6601755 1.00 PARP1 (0.56) PARP1PARP3SMN1; SMN2TNKSTNKS2
SCHEMBL6167453 0.83 ITGB3 (0.46) PARP1PARP3PIN1IDO1TDO2
SCHEMBL5406933 0.82 PIN1 (0.61) SMN1; SMN2PIN1ITGB3ITGA2BITGAV
SCHEMBL5406941 0.82 PIN1 (0.61) SMN1; SMN2PIN1ITGB3ITGA2BITGAV
SCHEMBL6614295 0.80 BRD4 (0.53) PARP1PARP3SMN1; SMN2TNKSTNKS2
SCHEMBL6528186 0.78 PIN1 (0.59) PARP1PARP3SMN1; SMN2KDM4EPIN1
SCHEMBL219151 0.77 TACR1 (0.68) CTSLCTSBCTSSCTSKITGB3
SCHEMBL7372270 0.77 TACR1 (0.68) CTSLCTSBCTSSCTSKITGB3
SCHEMBL220648 0.77 TACR1 (0.68) CTSLCTSBCTSSCTSKITGB3
SCHEMBL479010 0.77 TACR1 (0.68) CTSLCTSBCTSSCTSKITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389205-A1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS Ortho-McNeil Pharmaceutical Research Inc. (US) 2004-02-18 EP disclosed
WO-2002081467-A1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-10-17 WO disclosed